News Conference News AHA 2023 DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI Shelley Wood November 11, 2023
News Opinion Editor's Corner AHA 2023 What’s Going to Be Hot at AHA 2023 Shelley Wood November 07, 2023
News Daily News Lorundrostat, an Aldosterone Synthase Inhibitor, Passes Phase II Hurdle Todd Neale September 12, 2023
News Conference News ESC 2023 Early SGLT2 Inhibition, Spot Urine Sodium Checks May Help in Acute HF Todd Neale September 01, 2023
News Daily News First Drugs Chosen for Medicare Negotiations Hit Close to Home for Cardiologists L.A. McKeown August 31, 2023
News Daily News SGLT2i May Be Helpful Early After Acute MI in Diabetic Patients Todd Neale July 17, 2023
News Daily News Congestion Biomarker CA125 Signals Worse Outcomes in Ambulatory HFrEF Todd Neale July 03, 2023
News Daily News Andexanet Alfa, Reversal Agent for Factor Xa Inhibitors, Boosts Hemostasis Todd Neale June 05, 2023
News Conference News SCAI 2023 Repeat Revascularization Not Increased With Solo Ticagrelor: TWILIGHT Analysis L.A. McKeown May 22, 2023
News Features Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar L.A. McKeown May 12, 2023
News Daily News AI Gleans Insights Into Statin Questions, Misinformation Online L.A. McKeown April 26, 2023
News Daily News New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF L.A. McKeown April 19, 2023
News Daily News AHA/ACC Scientific Statement Supports Exercise Therapy in HFpEF L.A. McKeown March 27, 2023
News Daily News Borderline Cost-effectiveness for SGLT2 Inhibitors in HFpEF Todd Neale March 15, 2023
News Conference News ACC 2023 How Dapagliflozin Works in HFpEF: Some Clues From CAMEO-DAPA Todd Neale March 09, 2023
News Conference News ACC 2023 HALO: Baxdrostat No Better Than Placebo in Uncontrolled Hypertension Todd Neale March 08, 2023